Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 3/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.38 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.38 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24968556 | 1.00 | MAPT (0.42) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL24968563 | 0.98 | MAPT (0.40) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL24968269 | 0.91 | MAPT (0.50) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL24968265 | 0.91 | MAPT (0.50) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL25869679 | 0.87 | MAPT (0.52) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL24968565 | 0.87 | MAPT (0.52) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL24968559 | 0.85 | LPAR1 (0.40) | MAPTLPAR1LPAR3LPAR6LPAR4 | |
| SCHEMBL24968554 | 0.85 | LPAR1 (0.40) | MAPTLPAR1LPAR3LPAR6LPAR4 | |
| SCHEMBL25869635 | 0.85 | MAPT (0.49) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL24968266 | 0.84 | LPAR1 (0.39) | MAPTLPAR1LPAR3LPAR6LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
| WO-2023006062-A1 | NUCLEIC ACID VACCINES FOR MUTANT CORONAVIRUS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | MAPT 359/4885MAPK1 2433/4885PRKCA 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.